Sepracor Inc.

Recent Events

News & Analysis

jim edwards and sepracor inc. - All News and Analysis

• Sepracor Has Stopped Advertising Lunesta, But Sales Still Go Up

  BNET - 2009-09-15

  Sepracor appears to have almost stopped advertising for sleeping pill Lunesta, and yet sales are still rising. Sepracor spent less than $1 million on ads for the brand in 2009, but Lunesta sales were up 2 percent to $151 million in Q2 2009. by Jim Edwards

  Tags: Advertisement, Sepracor Inc., Sales Strategy, Sales Force Management, Sales, Jim Edwards

• Sepracor Sued Over Dainippon's Low Offer Despite Absence of Competing Suitors

  BNET - 2009-09-10

  Some Sepracor shareholders have sued the company's board alleging that their acceptance of Dainippon Sumitomo's acquisition offer of $23 a share, a premium of just 27.6 percent, isn't such a great deal. BNET suggested this might happen on Sept. 3. by Jim Edwards

  Tags: Absence, Sepracor Inc., Corporate Governance, Mergers & Acquisitions, Workforce Management, Corporate Law, Financial Accounting, Business Operations, Investment, Finance, Human Resources, Jim Edwards

• The Dainippon-Sepracor Deal Worst-Case Scenario

  BNET - 2009-09-03

  Holders of Sepracor stock considering Dainippon's offer of $23 a share to take over the company might want to ask themselves, might this company be willing to pay more than a 27.6 percent premium? A brief look at the two companies suggests that Dainippon needs this more than Sepracor, and...

  Tags: Sepracor Inc., Investment, Finance, Jim Edwards

• Sepracor Q2: More Miracles From Marlborough

  BNET - 2009-07-24

  Sepracor has once again achieved the impossible by growing sales of its sleeping pill Lunesta despite an almost infinite number of generic and OTC competitors. Lunesta sales were up 2 percent to $151 million in Q2 2009, the company reported. by Jim Edwards

  Tags: Sepracor Inc., Sales Strategy, Sales Force Management, Sales, Jim Edwards

• Sepracor Tested Sleeping Pill Lunesta on Kids

  BNET - 2009-07-06

  The FDA stopped two clinical trials run by Sepracor studying sleeping pill Lunesta in children. The July 4 weekend is traditionally one of those times when companies drop bad news into the media in the hopes that America will be too busy eating and drinking to notice. This year was...

  Tags: Sepracor Inc., Federal Government, Healthcare, Government, Jim Edwards

• End of Sepracor-GSK Deal Raises Question in Lunesta Patent Fight

  BNET - 2009-06-13

  Here's something that few noticed in Sepracor's Q1 2009 earnings announcement: The company's $155 million marketing deal for insomnia drug Lunesta/Lunivia with GlaxoSmithKline in Europe fell through. The collapse of the deal was predictable. I noted in July 2008 that GSK's subsequent $3.3 billion deal with Actelion...

  Tags: Patent, Sepracor Inc., GSK, Jim Edwards

• Sanofi, Sepracor Keep Local Politicians in Thrall Over Taxes

  BNET - 2009-03-30

  Two separate moves, by Sanofi-Aventis and Sepracor, illustrate the power that drug companies can have over the taxes of towns they base their headquarters in. Sanofi backed out of a deal in Pennsylvania that would have saved it 10 years of taxes in order to cut its...

  Tags: Sepracor Inc., Sanofi, Taxes, Free Trade, Personal Finance, Financial Planning, Finance, Jim Edwards

• Insomnia and Antidepressant Sales Give Lie to DTC Myths

  BNET - 2009-03-05

  Direct-to-consumer drug advertising has almost no relationship with consumer demand for prescriptions. That is one interpretation of a story in Ad Age showing that scrips for insomnia pills (such as Sanofi-Aventis's Ambien CR) and antidepressants (such as Eli Lilly's Cymbalta) are up, even though advertising in both those categories is...

  Tags: Advertisement, Sepracor Inc., Prescription, Drug Business, Sales Strategy, Sales, Jim Edwards

• Lilly, Barr, AZ and Sepracor Were Generous to Sen. Hatch's Utah Charity

  BNET - 2009-03-02

  Five drug and device companies, plus their lobbyist, PhRMA, are all very, very concerned about the welfare of Utah families. So concerned they gave $172,400 to the Utah Family Foundation over the last few years. By amazing coincidence, the foundation was founded by Sen. Orrin Hatch, who...

  Tags: Lobbyist, Pharmaceutical Company, Sepracor Inc., Utah, Orrin Hatch, PhRMA, Washington Times, Jim Edwards

• Ranking of 20 Drug Companies' Sales Forces Shows Productivity Flat or Declining

  BNET - 2009-02-24

  A ranking of drug company sales productivity shows Gilead gets the most revenues in return for every dollar invested in reps and marketing. At the other end of the table, Sepracor gets the least bang for its sales, general and administrative buck see table below. ...

  Tags: Revenue, Pfizer Inc., Sales Force, Drug Company, Genentech Inc., Sepracor Inc., Sales Strategy, Sales Force Management, Operational Accounting, Sales, Finance, Jim Edwards